Liquidia Technologies

Liquidia Technologies

Yahoo Finance • 21 hours ago

Will LQDA's Differentiated PAH Approach Drive Growth?

Liquidia Corporation LQDA is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (P... Full story

Yahoo Finance • 11 days ago

Why Liquidia Stock Was Diving This Week

Key Points The shares had risen by 155% year-to-date prior to earnings. Regardless, its one commercialized drug is doing well by any measure.10 stocks we like better than Liquidia › Liquidia(NASDAQ: LQDA) hasn't been the healthiest healt... Full story

Yahoo Finance • 14 days ago

Here are the major earnings before the open Wednesday

Major earnings expected before the bell on Wednesday include: * Nebius Group N.V. (NBIS [https://seekingalpha.com/symbol/NBIS]) * Tencent Holdings Limited (TCEHY [https://seekingalpha.com/symbol/TCEHY]) * Brinker International (EAT... Full story

Yahoo Finance • 20 days ago

3 Top Ranked Stocks Breaking Out Now

Regardless of what is happening in the world, whether geopolitical conflict, a cyclical downturn or the unwinding of an overleveraged hedge fund, a disciplined investment process remains the best tool for making consistent decisions with p... Full story

Yahoo Finance • 27 days ago

Liquidia Corporation to Report Second Quarter 2026 Financial Results on August 12, 2026

MORRISVILLE, N.C., July 29, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases,... Full story

Yahoo Finance • last month

Liquidia jumps as judge criticizes United Therapeutics in patent dispute

[Judge Gavel Beside Open Law Book With Turning Pages] jittawit.21/iStock via Getty Images Liquidia Corp. (LQDA [https://seekingalpha.com/symbol/LQDA]) rose 8% after a judge in a long-standing patent dispute with United Therapeutics (UTHR... Full story

Yahoo Finance • last month

Seeking Alpha’s Quant Spotlight: Highest and lowest rated healthcare stocks ahead of Q2

[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images The Health Care Select Sector SPDR® Fund ETF (XLV [https://seekingalpha.com/symbol/XLV]), which tracks the health ca... Full story

Yahoo Finance • last month

NVO Stock Up on EC Approval of Wegovy Pill to Treat Obesity

Novo Nordisk NVO received a boost after the European Commission (EC) approved once-daily oral version of Wegovy (semaglutide 25 mg) for the treatment of adults with obesity, with at least one weight-related comorbidity, alongside a reduced... Full story

Yahoo Finance • last month

Here’s Laughing Water Capital’s Updates on Liquidia Corp. (LQDA)

Laughing Water Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The second quarter was exceptionally good for the portfolio, with Class A investment i... Full story

Yahoo Finance • last month

Can LQDA's Yutrepia Drive Growth in the Competitive PAH Market?

Liquidia Corporation LQDA is banking on lead drug's Yutrepia's ability to sustain its strong commercial momentum despite intense competition in the pulmonary arterial hypertension (PAH) market. The drug is an inhaled dry-powder version of... Full story

Yahoo Finance • 2 months ago

IHE vs. PJP: Which Pharmaceutical ETF Is the Better Buy for Investors?

The iShares U.S. Pharmaceuticals ETF (NYSEMKT:IHE) offers lower fees and a higher dividend yield, while the Invesco Pharmaceuticals ETF (NYSEMKT:PJP) spreads its holdings more evenly across the sector's biggest players. Investors seeking... Full story

Yahoo Finance • 3 months ago

Liquidia Corporation Announces Inclusion in the S&P SmallCap 600® Index

Liquidia Technologies, Inc. MORRISVILLE, N.C., June 08, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respira... Full story

Yahoo Finance • 3 months ago

Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

NEW YORK, June 5, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 22, 2026, to coincide with the... Full story

Yahoo Finance • 3 months ago

Marvell stock pops after S&P 500 inclusion announcement

Investing.com -- Marvell Technology Inc (NASDAQ:MRVL) shook off a sharp two-day slump in postmarket trade Friday following the announcement of its upcoming inclusion in the bellwether S&P 500 index. Shares of the semiconductor company boun... Full story

Yahoo Finance • 3 months ago

Amarin dealt blow as Supreme Court upholds 'skinny labels' for generics

[Supreme Court of the United States. Washington DC, USA.] Mindaugas Dulinskas The Supreme Court unanimously sided with generic drugmaker Hikma (HKMPF [https://seekingalpha.com/symbol/HKMPF]) and against Amarin Corp. (AMRN [https://seeking... Full story

Yahoo Finance • 3 months ago

State Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio?

The State Street SPDR S&P Pharmaceuticals ETF(NYSEMKT:XPH) offers a lower-cost entry into the drug manufacturing space, while the First Trust NYSE Arca Biotechnology Index Fund(NYSEMKT:FBT) provides concentrated exposure to biotechnology.... Full story

Yahoo Finance • 3 months ago

Liquidia targets at least $1B net revenue in 2027 as YUTREPIA Q1 net product sales rise 44% sequentially

Earnings Call Insights: Liquidia (LQDA) Q1 2026 MANAGEMENT VIEW * "Three full quarters into the commercial launch of YUTREPIA, I would summarize the state of our business with 3 main points" (CEO & Director Roger Jeffs). "YUTREPIA is n... Full story

Yahoo Finance • 3 months ago

Liquidia Q1 Earnings Call Highlights

Liquidia logo MarketBeat Week in Review: 12/25 - 12/29 Liquidia (NASDAQ:LQDA) reported sharply higher first-quarter 2026 sales and profitability as executives said the launch of YUTREPIA continued to gain traction in pulmonary arterial h... Full story

Yahoo Finance • 3 months ago

Liquidia (LQDA) Shares Rise After Strong Q1 Earnings and Revenue Beat

medical research 16 ©Rawpixel Liquidia Corporation (NASDAQ:LQDA) shares gained nearly 3% in premarket trading on Monday after the biopharmaceutical company reported first-quarter results that exceeded analyst expectations on both earnings... Full story

Yahoo Finance • 4 months ago

This Biotech Stock Has Soared 175%. Here’s Why One Fund Still Sold $3 Million Worth

On May 8, 2026, JW Asset Management reported selling 83,600 shares of Liquidia Corporation(NASDAQ:LQDA), an estimated $3.10 million trade based on quarterly average pricing. What happened According to an SEC filing dated May 8, 2026, JW... Full story